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Abstract
Background: Acute lymphoblastic leukemia (ALL) is not a single uniform disease. It consists of several subgroups
with different cytogenetic and molecular genetic aberrations, clinical presentations and outcomes. Banding
cytogenetics plays a pivotal role in the detection of recurrent chromosomal rearrangements and is the starting
point of genetic analysis in ALL, still. Nowadays, molecular (cyto)genetic tools provide substantially to identify
previously non-detectable, so-called cryptic chromosomal aberrations in ALL. However, ALL according to banding
cytogenetics with normal karyotype - in short cytogenetically normal ALL (CN-ALL) - represent up to ~50 % of all
new diagnosed ALL cases. The overall goal of this study was to identify and characterize the rate of cryptic alterations
in CN-ALL and to rule out if one single routine approach may be sufficient to detect most of the cryptic alterations
present.
Results: Sixty-one ALL patients with CN-ALL were introduced in this study. All of them underwent high resolution
fluorescence in situ hybridization (FISH) analysis. Also DNA could be extracted from 34 ALL samples. These DNA-samples
were studied using a commercially available MLPA (multiplex ligation-dependent probe amplification) probe set directed
against 37 loci in hematological malignancies and/or array-comparative genomic hybridization (aCGH). Chromosomal
aberrations were detected in 21 of 61 samples (~34 %) applying FISH approaches: structural abnormalities were
present in 15 cases and even numerical ones were identified in 6 cases. Applying molecular approaches copy number
alterations (CNAs) were detected in 27/34 samples. Overall, 126 CNAs were identified and only 34 of them were
detectable by MLPA (~27 %). Loss of CNs was identified in ~80 % while gain of CNs was present in ~20 % of the
126 CNAs. A maximum of 13 aberrations was detected per case; however, only one aberration per case was found in 8
of all in detail studied 34 cases. Of special interest among the detected CNAs are the following new findings:
del(15)(q26.1q26.1) including CHD2 gene was found in 20 % of the studied ALL cases, dup(18)(q21.2q21.2) with
the DCC gene was present in 9 % of the cases, and the CDK6 gene in 7q21.2 was deleted in 12 % of the here in
detail studied ALL cases.
Conclusions: In conclusion, high resolution molecular cytogenetic tools and molecular approaches like MLPA
and aCGH need to be combined in a cost-efficient way, to identify disease and progression causing alterations in
ALL, as majority of them are cryptic in banding cytogenetic analyses.
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Background
Acute lymphoblastic leukemia (ALL) is a malignant dis-
ease of the hematological system with clonal proliferation
of lymphoid progenitor cells. It arises from genetic alter-
ations that block precursor B and T cell differentiation
and predominantly affects children [1]. B-ALL constitutes
80-85 % of ALL cases and T-ALL the remainder ones. B-
ALL patients have a favorable prognosis with an overall
complete remission rate of 95 % for pediatric (children
and adolescent between 1–15 years) but of only 60 % for
adults. Adverse prognosis in T-ALL was correlated with
presence of hyperleukocytosis, enhanced mediastinal
mass, central neural system involvement, male gender and
advanced age [1–5]. Cytogenetically detectable structural
or numerical chromosomal abnormalities are detected
in ~50 % of ALL cases. Such aberrations have prognos-
tic significance [1, 6]. High hyperdiploidy (51–65 chro-
mosomes) has been connected with good survival and
excellent outcome in B-ALL, while hypodiploidy (<44
chromosomes) has an adverse prognosis [7–9]. Recur-
rent structural chromosomal abnormalities found in
ALL can also be reciprocal translocations. ALLs with a
translocation t(12;21)(p13;q22) leading to the ETV6/
RUNX1 gene-fusion are more likely to be cured, than
those with a translocation t(9;22) or t(4;11), which tend
to have unfavorable outcomes. Complex karyotypes, in-
cluding three to five or more chromosomal abnormalities,
are typically found in ~5 % of ALL cases and are also asso-
ciated with an adverse outcome [10]. Finally, ALL cases
with according to banding cytogenetics normal karyotype -
in short cytogenetically normal ALL (CN-ALL) - are classi-
fied into intermediate risk group [6, 11, 12]. Malignant bone
marrow of T-ALL patients shows a normal karyotype more
frequently than those of B-ALL patients. Accordingly in
those cases cytogenetic markers cannot be determined and
therapeutic decisions may be hampered.
Based on the knowledge that chromosomes in ALL
show a low banding resolution and that a good part of
ALL cases present with a normal karyotype, it is not far
to seek, that small aberration can easily be missed
when analyzing ALL derived chromosomes by banding
cytogenetics alone [6, 13]. Copy number alterations
(CNAs) at the microscopic or submicroscopic level, i.e.
focal deletions, but also duplications or sequence/point
mutations in genes that primarily serve as transcrip-
tional regulators of the lymphoid developmental pathway
can nowadays be detected by approaches like multiplex
ligation-dependent probe amplification (MLPA) or array-
comparative genomic hybridization (aCGH) [12, 14, 15].
The present study includes 61 CN-ALL cases, which
were retrospectively studied for the rate of cryptic (sub)-
chromosomal changes to rule out if one single molecular
(cyto)genetic routine approach may be sufficient to de-
tect most if not all of the cryptic alterations present.
Results
Standard cytogenetic analysis by G-banding revealed
normal karyotypes in 61 ALL cases included in this
study (Additional file 1: Table S1). In a first step all 61
cases were studied by the whole genome oriented fluor-
escence in situ hybridization (FISH)-banding based probe
set multitude multicolor banding (mMCB) [16]. For fur-
ther delineation of mMCB results appropriate FISH-
probes and probe sets were applied (Additional file 1:
Table S1). Based on these results 21/61 (34 %) cases were
not cytogenetically normal but had gross acquired
chromosomal aberrations: structural abnormalities were
found in 15/61 cases (24 %) and even numerical ones were
observed in 6/61 cases (10 %) (Table 1). Overall, in GTG-
banding cryptic balanced and unbalanced translocations,
derivative chromosomes, isochromosomes, interstitial de-
letions, inverted duplications and/or numerical aberrations
were identified in 34 % of the studied CN-ALL cases by
means of molecular cytogenetics. In Fig. 1 case P66 is ex-
emplified with a three-way translocation between chromo-
somes #10, #11 and #14, inversion of second chromosome
# 14 and insertion (11;10). The breakpoints of this P66
case were characterized as 10p12.3, 10q11.23, 11p15.3,
11q23.3, 14q11, 14q24.2, and 14q32.3.
34/61 studied CN-ALL cases (18 B-ALL, 8 T-ALL and
8 with undefined ALL) were studied further using MLPA
and aCGH. Overall, 126 CNAs were detected by MLPA
and aCGH in those cases. CNAs were identified in 27/
34 (80 %) of the studied cases. 1 to 13 CNAs per case
were detected (Table 1). The distribution of CNAs per
chromosome and frequencies of gains and losses are
summarized in Fig. 2; i.e. all chromosomes apart from 8
and Y were involved in CNAs in this study.
Deletions and duplications could be grouped accord-
ing to their sizes as follows:
– focal CNAs (e.g. deletion of CHD2 gene in 7 cases
or duplication of DCC gene in 3 cases – Table 1);
– CNAs involving variable numbers of genes (e.g.
deletion on 9p21.3 in 8 cases or amplification of
9q34.12q34.13 in one case – Table 1);
– CNAs involving large parts of whole chromosomal p
and/or q arms (e.g. deletion on 4p16.3p14 in one case
or duplication of 7p22.3p14.1 in one case – Table 1)
– CNAs of whole chromosomes (e.g. monosomy X in
one case or trisomy #14 in one case – Table 1).
Most frequently observed deletion was 9p21.3 in 8/34
ALL cases (3x in B-ALL, 4x in T-ALL and 1x in undefined
ALL); the CDKN2A/B genes were affected in all these eight
cases. Furthermore, PTEN in 10q23.31 (6/34) and IKZF1 in
7p12.2 (5/34) were the hit by deletions regularly. Besides,
deletion in 15q26.1 (CHD2 gene) was detected in 7/34
cases and duplication in 18q21.2 (DCC gene) in 3/34 cases.
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Table 1 Summary of aberrations detected by metaphase directed FISH, interphase FISH to determine the percentage of specific aberrations, and aCGH in 34 ALL patients







P1 1 46,XX normal normal dup(11)(p15.5p15.4) chr11:1,960,555-3,626,932 1,666,377
P8 30 47,XY,+21[5]/46,XY[2] dup of 21q22.12 RUNX1: dup (72 %) n.d. n.d. n.d.
P13 34 46,XY[8] del of 10q23.3 del(10)(q23.2q23.31) chr10:88,906,902-91,189,599 2,282,697
del of 17p13.1 TP53: del (9 %) del(17)(p13.1p13.1) chr17:7,579,695-8,281,928 702,233
P17 27 46,XX[7] n.d. normal normal n.d. n.d.
P23 59 del(3)(p25.3p25.3) chr3:10,179,706-10,385,195 205,489
del of 7p12.2 del(7)(p12.2p12.2) chr7:50,337,405-50,482,274 144,869
del(10)(q23.3q23.3) chr10:89,570,600-89,676,741 106,141
del(11)(q14.2q14.2) chr11:85,683,188-85,944,362 261,174
47,XX,+14[2]/ IGH: dup (58 %) +14 +14 107,349,540





P28 84 46,XY, del of 7p12.2 del(7)(p12.2p12.2) chr7:50,353,062-50,444,269 91,207
t(9;22)(q34;q11), del of 9p21.3 CDKN2A/B: del (75 %) del(9)(pterp11.2) chr9:0–47,212,321 47,212,321
del(11)(q13q25)[7] del of 9p13.2 del(9)(q34.2qter) chr9:136,917,580-141,213,431 4,295,851
del(10)(q23.3q23.3) chr10:89,619,806-89,731,258 111,452
del of 11q22.3 BIRC3: del (75 %) del(11)(q13.2qter) chr11:67,773,863-135,006,516 67,232,653
ATM: del (77 %) del(15)(q26.1q26.1) chr15:93,412,860-93,450,773 37,913
MLL: del (80 %) dup(20)(q11.23q12) chr20:37,305,876-39,130,131 1,824,255
del(20)(q12q13.12) chr20:39,245,111-45,524,952 6,279,841
dup(20)(q13.12q13.12) chr20:45,524,953-45,780,811 255,858
del(20)(q13.12q13.32) chr20: 45,780,812-58,067,678 12,286,866
del(21)(q22.2q22.2) chr21:39,764,621-39,807,169 42,548
BCR: del (94 %) del(22)(q11.23q11.23) chr22:23,584,037-23,592,537 8500
P43 69 46,XX, normal TFG: dup (15 %) dup(3)(q12.2q12.2) chr3:100,360,682-100,444,109 83,427
der(4)(4pter- > 4q21.3::11q23.3- del(7)(q21.2q21.2) chr7:92,252,341-92,475,197 222,856




















P48 39 46,XY, n.d. del(6)(q13q14.2) chr6:73,331,571-84,140,938 10,809,367
t(6;11)(q15;p12), del(6)(q16.2q21) chr6:99,282,580-109,703,762 10,421,182
ins(6;11)(q22.1;q13q14), del(6)(q22.31q22.33) chr6:124,125,069-128,841,870 4,716,801
inv(6)(q15q25.3), ESR1: del (89 %) del(6)(q25.1q25.3) chr6:151,725,897-157,531,913 5,806,016
del(11)(q21q23.2)[8] del(7)(p12.2p12.2) chr7:49,991,954-51,207,236 1,215,282
dup(11)(p15.5p15.4) chr11:1,925,114-3,143,116 1,218,002
WT1: del (91 %) del(11)(p15.1p12) chr11:20,546,133-37,403,781 16,857,648
BIRC3: del (90 %) del(11)(q14.1q14.3) chr11:85,157,088-88,557,421 3,400,333
ATM: del (77 %) del(11)(q22.1q22.3) chr11:100,992,179-114,667,959 13,675,780
del(13)(q14.2q14.2) chr13:48,980,623-49,148,073 167,450
P49 39 46,XX[10] n.d. normal dup(11)(p15.5p15.4) chr11:2,016,406-3,430,378 3,430,378
P51 59 46,XX[6] normal normal del(10)(p12.1p12.1) chr10:28,057,099-28,220,314 163,215
del(15)(q26.1q26.1) chr15:93,412,860-93,450,773 37,913
del(X)(q21.1q21.1) chrX:76,875,639-77,157,819 282,180
P52 21 46,XY[4] normal del(6)(p21.1p21.1) chr6:45,395,872-45,409,919 14,047
del(7)(q21.2q21.2) chr7:92,149,393-92,495,958 346,565






P53 34 46,XY[5] normal normal dup(22)(q11.21q11.21) chr22:18,706,001-21,561,514 2,855,514
P55 19 46,XY[6] del of 17p13.1 TP53: del (100 %) del(17)(pterp11.2) chr17:0–20,219,464 20,219,464
−20 −20 63,025,520
P56 47 45,XY,-21[2]/ normal normal del(12)(pterp11.21) chr12:0–31,260,891 31,260,891
46,XY[4]
P57 56 46,XY[3] normal normal normal n.d. n.d.
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der(14)(pter- > q32::q32- >
q13::q32- > qter)[10]
del of 9p21.3 CDKN2A/B: del (74 %) del(9)(p21.3p21.3) chr9:21,252,517-24,289,720 3,037,203
del(10)(p15.3p15.3) chr10:1,491,986-1,582,072 90,086
IGH: split (78 %) dup(14)(q13q32.33) chr14:35,918,265-106,513,022 70,594,757
del(16)(q13q13) chr16:57,275,940-57,331,138 55,198
del(21)(q22.2q22.2) chr21:39,764,621-39,895,171 130,550
P64 5 46,XX, n.d. del(5)(q31.3q32) chr5:142,096,863-145,891,069 3,794,206
t(16;19)(p11.2;q13.3),
der(5)t(5;9)(q31;p13.2), CDKN2A/B: del (86 %) del(9)(p21.3p21.3) chr9:21,218,548-23,002,377 1,783,829
der(9)t(5;9)(q31;p13.2),
der(9)t(9;9)(q34;p13.2)[10] FUS: split (75 %)













P5 22 46,XX[12] normal normal normal n.d. n.d.
P6 16 47,XY, normal normal






P7 26 46,XY, del of 9p21.3 CDKN2A/B: del (64 %) del(9)(p21.3p21.3) chr9:21,817,082-23,515,821 1,698,739
t(2;9;18)(p23.2;p21.3;q21.33), del of 13q14.2 RB1: del (25 %) del(13)(q14.2q14.2) chr13:48,982,463-49,062,316 79,853
t(10;14)(q24;q11)[10] del(16)(p13.3p13.3) chr16:3,154,954-4,568,792 1,413,838
P18 36 46,XY[5] dup of 18q21.2 DCC: dup (13 %) n.d. n.d. n.d.
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+21, del of 6q27
t(10;14)(q24;q11), del of 9p21.3 CDKN2A/B: del (89 %)
del(6)(q15q27)[6] del of 12p13.2 ETV6: del (78 %)
del of 13q14.3 DLEU1: del (15 %)
dup of 21q22.1 RUNX1: dup (78 %)




del of 9p21.3 CDKN2A/B: del (92 %) del(9)(pterp11.2) chr9:0–47,212,321 47,212,321








P38 22 46,XY[3] normal normal normal n.d. n.d.
P61 18 46,XX,der(2)t(2;7)(q37.3;q34),
t(7;10)(q34;q24.1 ~ 25.1) [4]/
del(1)(p36.31p36.23) chr1:5,958,728-7,238,618 1,279,890
del(4)(p16.3p14) chr4:3,072,509-38,882,925 35,810,416
46,XX[3] dup of 6q23.3 MYB: amp (90 %) dup(6)(q23.3q23.3) chr6:134,245,761-136,118,354 1,872,593
del of 9p21.3 CDKN2A/B: del (88 %) del(9)(p21.3p21.3) chr9:21,252,517-23,002,377 1,749,860
ABL1: amp (95 %) dup(9)(q34.1q34.1) chr9:133,658,293-134,092,544 434,251
FGFR2: del (57 %) del(10)(q25.1q26.3) chr10:112,392,101-135,534,737 23,124,636
B- or T ALLs (not clinically well defined)
P11 26 46,XY[8] n.d. normal normal n.d. n.d.
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del of 9p21.3 CDKN2A/B: del (81 %) del(9)(p21.3p21.3) chr9:20,279,653-22,555,566 2,275,913
del(10)(p14p13) chr10:6,889,266-12,484,159 5,594,893
del of 12p13.2 ETV6: del (91 %) del(12)(p13.2p13.1) chr12:11,761,018-12,934,870 1,173,852
del(18)(p11.32p11.31) chr18:2,741,687-3,231,531 489,844
P21 62 46,XY[11] n.d. normal normal normal normal
P24 23 46,XY[12] dup of 18q21.2 DCC: dup (18 %) n.d. n.d. n.d.
P30 46 46,XY[6] normal normal n.d. n.d. n.d.
P33 76 45,X,-X[8] del(4)(q24q24) chr4:106,036,993-106,601,946 564,953
del(7)(q21.2q21.2) chr7:92,080,855-92,475,197 394,342
dup(7)(q36.2q36.2) chr7:153,039,830-154,467,634 1,427,804
del of 10q23.3 del(10)(q23.3q23.3) chr10:89,610,886-89,698,312 87,426
del(15)(q21.2q21.2) chr15:51,826,924-51,919,665 92,741
del(15)(q26.1q26.1) chr15:93,433,130-93,450,773 17,643
del of 17p13.1 TP53: del (10 %) del(17)(p13.1p13.1) chr17:7,583,457-8,156,734 573,277
del(17)(q11.2q11.2) chr17:30,259,193-30,267,204 8011




P46 63 46,XY[8] normal dup(6)(q25.3q25.3) chr6:157,944,961-158,033,908 88,947
del of 7p12.2 del(7)(p12.2p12.2) chr7:50,452,798-50,492,798 40,000
dup(17)(q12q12) chr17:36,046,040-36,095,204 49,164
P47 59 46,XX[6] normal dup(1)(p13.3p13.3) chr1:107,921,895-107,970,781 48,886
del of 7p12.2 del(7)(p12.2p12.2) chr7:50,356,873-50,465,376 408,503



















Cytogenetic analysis has been and still is the standard
method for detection of diagnostically relevant recurrent
chromosomal aberrations in ALL. It is well known that
when using banding karyotyping cryptic chromosomal
aberrations may be missed due to several reasons: (i)
sensitivity of chromosomal banding techniques is lim-
ited, even in case of good chromosomal morphology, to
aberrations being at least 10 Mb in size, (ii) aberrations
may be cryptic or masked, i.e. they are not resolvable
due to a similar or identical GTG-banding pattern and/
or poor chromosome morphology, and (iii) metaphases
may be difficult to obtain and to evaluated as chromo-
somes may not be well-spread, clumsy or appearing as
fuzzy with indistinct margins; thus even numerical aber-
rations may be missed [6, 13, 17].
In the past molecular cytogenetic approaches have
shown to be efficient to detect in banding cytogenetics
cryptic chromosomal aberrations [6, 13, 17]. Besides in
metaphase also interphase nuclei can be studied in case
of low mitotic (non-dividing) cells and also alterations
being at low mosaic level can be easily detected by that
approach [12, 14, 18]. In this study, we detected previ-
ously cryptic aberrations in 21/61 (34 %) cases with
ALL using metaphase directed FISH studies; even com-
plex aberrations were identified in some of these cases
(Table 1 and Additional file 1: Table S1).
For 34/61 cases DNA could be extracted from the cy-
togenetically worked up cell suspension. Thus, in those
cases besides FISH also MLPA and aCGH could be ap-
plied additionally, i.e. approaches which have much
higher resolution than FISH, but can only detect unbal-
anced aberrations and no low level mosaics. Using
these approaches cryptic CNAs were detected in ~80 %
of those ALL cases. All 126 CNAs detected by MLPA and
aCGH have been checked by UCSC genome browser to
exclude benign copy number variations (CNVs) (http://
genome-euro.ucsc.edu/cgi-bin/hgGateway?redirect=au-
to&source=genome.ucsc.edu). Thus, all of them most
likely are leukemia-related genetic changes, which were
recognized in 27/34 ALL cases.
Of special interest may be a novel recurrent submicro-
scopic CNA expressed as loss of 15q26.1: focal deletion of
CHD2 gene located there was found in 7 of the 34 (20 %)
studied ALL cases in this study. The CHD2 gene is a
member of the chromodomain helicase DNA-binding
(CHD) protein family, which are all characterized by a
chromatin-remodeling domain (the chromodomain) and
an SNF2-related helicase/ATPase domain [19]. Thus, in
future it may be of interest to study CHD2 gene deletions
also for presence of mutations in this gene and also to
screen ALL patients in general for CHD2 gene mutations.
Besides, duplication of DCC gene in 18q21.2 was
present in 3 of the 34 (9 %) studied cases. DCC is a mem-
ber of the immunoglobulin superfamily of cell adhesion
Figure 1 Result of aMCB probesets for chromosomes 10, 11, and 14
are shown, which characterized the breakpoints seen in case P66 as
10q11.23, 11p15.3, 14q11, 14q24.2, and 14q32.3. The final karyotype
after application of all approaches as summarized in Additional file 1:
Table S1 was 46,XX,der(10)(10pter- > 10p12.31::11q23.3- >
11q23.3::10p12.31- > 10q11.23::14q24.2- > 14qter),der(11)(10qter- >
10q11.23::11p15.3- > 11q23.3::10p12.31- > 10p12.31::11q23.3- >
11qter),der(14)t(11;14)(q15.3;q24.2),inv(14)(q11q23)
Figure 2 Distribution of CNAs as detected by aCGH in 27/34 studied cases. On X-axis the chromosome number is shown, while on Y-axis the
total number of CNAs for each chromosome is depicted (scale 2).
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molecules and acts as a transmembrane dependence
receptor for netrins, key factors in the regulation of axon
guidance during development of the central nerve system.
Amplification of DCC gene was previously reported in
chronic lymphocytic leukemia (CLL) [20, 21], however,
this is the first report for DCC gene amplification in ALL.
To evaluate the role of the DCC gene and to elaborate its
potential as a molecular marker in ALL still needs more
studies.
In general, submicroscopic CNAs were identified most
frequently in chromosomes #7 and #9. CNAs in #7 in-
volved deletion of IKZF1 at 7p12.2 that encodes IKAROS
protein and is required for the development of all lymph-
oid lineages in 5 of 34 (14 %) studied CN-ALL cases.
According to the literature deletions and/or sequence mu-
tations of IKZF1 are present in 15 % of pediatric B-ALL,
including ~70 % of BCR-ABL–positive ALL and with
high-risk of relapse ~30 % of BCR-ABL–negative B-ALL
[22]. However, deletions of IKZF1 are predominantly
monoallelic and involve the N-terminal zinc-finger do-
main of IKAROS protein and result in expression of
dominant-negative isoforms with cytoplasmic localization
and oncogenic activity as well as an association with very
poor outcome [23, 24]. Thus, IKZF1 has newly been con-
sidered as a prognostic marker for B-ALL and might be
useful for risk stratification [24, 25].
Cyclin dependent kinase 6 (CDK6) at 7q21.2, is the cata-
lytic subunit of a protein kinase complex that regulates cell
cycle G1 phase progression and G1/S transition. Deletion
of CDK6 was identified in this study in 4 of 34 (12 %) of
ALL cases. It has been shown recently that inhibition of
CDK6 may lead to overcome the differentiation block seen
in acute myelogenous leukemia (AML) with MLL translo-
cations [26]. Further studied for this gene may also be
recommended for better understanding of ALL biology.
The majority of #9 abnormalities is involving deletions
of cell cycle regulatory genes at 9p21.3. The main target
to deletions is CDKN2A which encodes for the two tran-
scripts p16/INK4A and p14/ARF (alternative splicing),
followed by CDKN2B gene (p15/INK4B); both are tumor
suppressor genes. Deletions of CDKN2A/B can be found
in 30 and 50 % of B-ALL and T-ALL cases, respectively
[23, 25, 27]. In the present study such deletions were
only found in 8/34 (24 %) of the studied ALL cases,
which is most likely due to low case numbers.
CDKN2A/B deletion can be detected at initial diagnosis
or acquired at relapse, suggesting that CDKN2A/B dele-
tion is a secondary genetic event. Also, the outcome of
cases with CDKN2A/B deletion depends on the status of
the second allele, as homozygous deletions are associ-
ated with poor outcome and heterozygous deletions
represent markers for favorable outcomes [27, 28]. T-
ALL-case P61 had such a prognostically adverse homo-
zygous deletion in 9p21.3 together with amplification of
9q34.12 to 9q34.13; the latter contains the ABL1 and
NUP214 genes (Fig. 3). NUP214-ABL1 fusion gene amp-
lification was previously mainly observed in T-ALL and
associated with poor outcome [6].
Figure 3 aCGH from case Nr. P61 showed two CNAs in chromosome 9; at 9p21.3 a homozygous deletion (arrowhead) and at 9q34.12 to 9q34.13
an amplification (arrow). a FISH confirmed presence of the homozygous deletion in 9p21.3 in interphase. b An amplification present as double
minutes was confirmed using a probe specific for the ABL-gene
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Another recurrent deletion in #9 in the studied ALL
cases involved the PAX5 gene located in 9p13.2, which
encodes for a protein with key roles in lymphoid devel-
opment. It was found to be deleted in B-ALL (n = 2) and
T-ALL (n = 1 showed short arm 9p deleted) in this study.
In the literature, deletion of PAX5 was reported in
31.7 % of B-ALL and also it has been involved in several
chromosomal translocations [29, 30]. In a recent report,
PAX5 deletion was observed in only 10 % and 18 % in
children and adult B-ALL, respectively; notably PAX5
deletion was frequently accompanied by deletion of
CDKN2A (83.3 % of children and 100.0 % of adults)
[28]. Also PAX5 was found to be a common target in
leukemogenesis of B-ALL, but not associated with ad-
verse outcome [15]. In future, PAX5 could be used as
one of the molecular markers in diagnosis and monitor-
ing of the disease, especially in B-ALL [28–30].
Besides, other CNAs have been identified here,
encompassing single or few genes, only. Many of CN
losses involve cell cycle regulatory and/or putative tumor
suppressor genes like 10q23.3 (PTEN; n = 6), 13q14.2
(RB1; n = 3), and 17p13.1 (TP53; n = 4), or transcrip-
tional regulators and co-activators like 3q26.32
(TBL1XR1; n = 1), 12p13.2 (ETV6; n = 2), 21q22.12
(RUNX1; n = 1) and 21q22.2 (ERG; n = 2), or regulators
of chromatin structure and epigenetic regulators like
16p13.3 (CREBBP; n = 2). Although, oncogene overex-
pression resulting from gene duplication is infrequent in
ALL, we found MYB duplication in one case, too. These
observations of gene loss of function or overexpression
being involved in leukemic transformation [15, 31]
underline the heterogeneity of different ALL cases and
the potential of molecular approaches to identify new
subgroups of this disease.
The present study also highlights, that most likely all
CN-ALL cases hold cryptic genomic alterations. DNA
sequencing and single-nucleotide polymorphism (SNP)
arrays have been used to detect mutations for a number
of target genes that are known to key roles in lymphoid
development. Thus, somatic mutations have been identi-
fied in both B and T-ALL patients [2]. For instance,
mutations in JAK2 were identified in 10 % of high-risk
childhood B-ALL and shown to be associated frequently
with other abnormalities, including deletions or muta-
tions of IKZF1 and overexpression the CRLF2 gene [23].
In T-ALL, NOTCH1-activating gene mutation has been
found in 60 % and FBXW7-inactivating gene mutation
occurs in 20 % of pediatric T-ALL [32]. Less commonly,
mutations in PTEN, WT1, amplification of MYB and
sequence mutations in RAS signaling (NRAS, KRAS, and
NF1) and tumor suppression (TP53) have been identified
in ALL [8, 31].
Overall, sensitive methods to detect cryptic chromo-
somal aberrations in CN-ALL are useful and necessary for
genetic risk–based classification and correct determin-
ation of treatment protocols. The present study highlights
that molecular cytogenetic approaches together with mo-
lecular methods are suited to identify cryptic rearrange-
ments and potential target genes that involved in
leukemogenesis and progression of the disease. Also it
could be demonstrated that aCGH is a highly efficient
tool for detection of CNAs in CN-ALL. However, while
aCGH (and MLPA) provide data on imbalanced genomic
alterations, (molecular) cytogenetics additionally detects
different leukemic subclones within one sample, as well as
balanced translocations leading to tumor-specific fusion
genes. It seems to be valid, that there is no leukemia clone
without genetic alterations; we just have to use the appro-
priate techniques to identify them. In conclusion, to obtain
a comprehensive picture of all relevant changes in each in-
dividual ALL case data from cytogenetics, FISH, MLPA
and aCGH needs to be considered and included in diag-
nostics; however, sometimes such investigations may be
hampered by lack of sufficient cellular material, as also in
this study, where only 34/61 cases could also be studied
on DNA level or other previous studies [16, 33].
Methods
Patients and sample preparation
Cell suspensions were obtained from bone marrow col-
lected from 61 patients diagnosed with ALL (31 with
B-ALL, 12 with T-ALL and 18 with undefined ALL;
Additional file 1: Table S1). The samples were obtained
under informed consent of the corresponding patients
and according to institutional ethical committee guide-
lines (ethical commission of the university clinic Jena,
Germany; code 1105-04/03).
GTG-banding
The bone marrow cells were unstimulated cultivated for
24 hours (with and without colchicin) and 48 h, and a
standard cytogenetic cell preparation following air drying
method was done [34]. GTG-banding was routinely done
in each sample following standard procedures. Twenty
metaphases were obtained for cytogenetic evolution on a
banding level of 250–300 bands per haploid karyotype
[35]. Apart from 4 all 61 studied cases had a normal
karyotype of 46,XX or 46,XY. In one case the karyotype
could not be determined due to low metaphase quality;
one case just had (most likely age associated) loss of an X-
chromosome in a subset of the cells, one case had a ques-
tionable der(19) in all cells, and another one a trisomy 14
in 6/20 studied cells.
Molecular cytogenetics
Fluorescence in situ hybridization was done according to
standard procedures and/or according to manufacturer’s
instructions.
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Homemade were the following probes and probe sets:
– 24-color-FISH using all human whole chromosome
painting (WCP) probes [36];
– FISH-banding probe-sets as follows: genome wide
multitude multicolor banding (mMCB) and
chromosome specific high resolution array-proven
multicolor-banding (aMCB) [16, 37, 38];
– WCP probes for all chromosomes were homemade
[36].
– The following commercially available locus-specific
probes (LSPs) (Additional file 2: Table S2) were used
to validate and possibly confirm the breakpoints
found in mMCB, aCGH and/or MLPA: from Abbott/
Vysis (Wiesbaden, Germany), Kreatech Diagnostics
(Amsterdam, Netherland), ZytoVision (Bremerhaven,
Germany), and DNA from bacterial artificial
chromosome (BACs) probes obtained from Resources
Center (Oakland, USA) were labeled by PCR with
SpectrumGreen, SpectrumOrange or TexasRed-dUTP
and applied in two- or three-color FISH-approaches.
For each interphase FISH analysis to determine the
percentage of specific aberrations, at least 200
interphase nuclei were examined per sample and
FISH-probe – the applied probes can be found in
Additional file 2: Table S2.
– Homemade and previously reported chromosome-
specific sub-CTM- (= subtelomere -/ subcentromere
oriented) probe-sets were applied in selected cases
[13] (Additional file 1: Table S1).
DNA isolation
Genomic DNA was extracted from cells fixed in acetic
acid-methonal (1:3) by Puregene DNA Purification Kit
(Gentra Systems, Minneapolis, MN, USA). DNA concen-
tration was determined by a Nanodrop spectrophotom-
eter. The quality of DNA was checked using agarose gel
electrophoresis. DNA-samples extracted from fixed cells
of 2 healthy males and 2 healthy females by the same
method were used as reference samples.
MLPA analysis
SALSA MLPA P377-A1 Hematologic malignancies
probemix was used for this study (MRC- Holland,
Amsterdam, The Netherlands). This probemix contains
probes for 37 genes covered by 54 probes, which have
diagnostic or prognostic significant role in hematologic
malignancies. MLPA was performed according to the
manufacturer’s protocol, which includes three reaction
phases: hybridization, ligation, and PCR amplification.
Amplified probes and GeneScan LIZ 500 (Applied
Biosystems, Foster City, USA) standard were separated
by capillary electrophoresis using a ABI-PRISM 3130XL
Genetic Analyzer (Applied Biosystems, Foster City, USA).
GeneMarker (SoftGenetics, USA) was used to analy-
zeMLPA data. Detection threshold was set at 0.65-1.35;
control samples of four healthy donors were included in
each run.
Array-comparative genomic Hybridization (aCGH)
aCGH was performed using Agilent SurePrint G3 Human
Genome microarray 180 K (Agilent Technologies, Santa
Clara, CA, USA), an oligonucleotide microarray contain-
ing 170,334 probes 60-mer with a ~13 kb overall median
probe spacing (11 kb in Refseq-genes). Genomic DNA of
patients was co-hybridized with a sex-mismatched control
DNA (G1471 or G1521; Promega, Mannheim, Germany).
Labeling was performed using Agilent Genomic DNA en-
zymatic labeling kit (Agilent) according to the manufac-
turers’ instructions. After hybridization and washing, the
aCGH slide was scanned on an Agilent scanner, processed
with Feature Extraction software (v12.0.2.2) and results
were analyzed using Cytogenomics (v3.0) using ADM2 as
aberration algorithm.
Additional files
Additional file 1: Table S1. All 61 CN-ALL cases studied; for each case
age, gender and subtype of ALL is given. Also all FISH-probes, probe sets
and approaches applied for each case are listed. Abbreviations: n.d. = not
determined, y = year.
Additional file 2: Table S2. List of locus specific probes used in the
present study for further characterization of acquired aberrations and/or
determination of the percentage of deletions or duplications as determined
by aCGH or MLPA.
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